NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tim C. Lienau who wrote (221)	10/21/1997 8:23:00 PM
From: Miljenko Zuanic	Read Replies (2) of 328

To all: Very strange move on strong market day. Even news by Reuters didn't help: >> Liposomal Amphotericin B Superior To Standard Formulation In AIDS Patients WESTPORT, Oct 21 (Reuters) - Liposomal Amphotericin B deoxycholate (AmBisome) appears to be a less toxic and more effective treatment for HIV-positive patients with cryptococcal meningitis compared with the standard Amphotericin B, according to a report by Dutch researchers that appears in the October issue of AIDS. Dr. Alexander C.A.P. Leenders of the University Hospital Rotterdam and colleagues note that the treatment of choice for AIDS-associated cryptococcal meningitis has been initial therapy with Amphotericin B, followed by Fluconazole maintenance. "However, the administration of Amphotericin B is associated with considerable toxicity." To investigate the possible advantages of the liposomal formulation, Dr. Leenders' group assigned 15 AIDS patients with cryptococcal meningitis to AmBisome and 13 other patients to standard Amphotericin B. They found that the time to clinical response in both groups was comparable. However, "AmBisome therapy resulted in a CSF [cerebral spinal fluid] culture conversion within 7 days in six out of 15 patients versus one out of 12 Amphotericin B-treated patients." Based on Kaplan-Meier estimates of time to CSF culture conversion, "...AmBisome was more effective." It was also "...significantly less nephrotoxic" than the standard compound. Although the high cost of AmBisome has been considered a drawback, Dr. Leenders' group points out that shorter hospitalizations, lower toxicity rates and shorter time of administration associated with AmBisome may compensate for the higher cost. Overall, they conclude that "...the AmBisome regime used in this study is probably the most effective single agent regimen for the treatment of AIDS-associated cryptococcal meningitis." AIDS 1997;11:1463-1471. << mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next